Late Effects


According to the APBMT Activity Survey results, the number of HSCT has increased steadily in most of the APBMT countries. The number of HSCT performed until 2007 was 84,967. Approximately 50% of the HSCT recipients become long-term survivors, thus, the estimated number of long-term survivors exceed 40,000 in the APBMT countries / region.

Long-term survivors without relapse of underlying disease could suffer from various late complications after HSCT, such as chronic GVHD, infection, organ dysfunction, skeletal and muscular problems, endocrine complications, gonadal dysfunctions, secondary malignancy, growth problems, and quality of life issues. It will be beneficial to study differences in the follow-up clinical practice, the incidence and risk factors of these late complications among the APBMT countries / regions.



Minutes of the Late Effects Working Group Meetings are available here
Click on the following links to download.
Note: Access to the document links within the Minutes pages is restricted to members only and requires a password.

Minutes of the Late Effects Working Group - Oct 2010

Minutes of the Late Effects Working Group - Nov 2013

Letter from chair - Late Effect Working Group



Chairman: Shinichiro Okamoto (Japan)

WG Members

Name Country Institute
Shinichiro Okamoto Japan Keio University
Yoshiko Atsuta Japan Nagoya University
Tahir Shamsi Pakistan National Institute of Blood Disease & Bone Marrow Transplantation
Micky Koh Singapore Deputy Director, Center of Transfusion Medicine Health Sciences Authority, Head-Bone Marrow Transplantation St George's Hospital and Medical School
David Ma Australia St Vincent's Hospital Sydney
Hoon Kook Korea Chonnam National University
Jong Wook Lee Korea Catholic University of Korea
Lin Kai-Hsin Taiwan National Taiwan University Hospital
Navin Khattry India Tata memorial hospital
Philip Rowlings Australia Calvary Mater Newcastle & HAPS
William YK Hwang Singapore Singapore General Hospital